Elsevier

Brain, Behavior, and Immunity

Volume 87, July 2020, Pages 155-158
Brain, Behavior, and Immunity

Plasmapheresis treatment in COVID-19–related autoimmune meningoencephalitis: Case series

https://doi.org/10.1016/j.bbi.2020.05.022Get rights and content

Highlights

  • COVID-19 patients failing to regain consciousness require neurological assessment.

  • Brain imaging and lumbar puncture are required to determine CNS involvement.

  • Neurological involvement during COVID-19 infection can be immune mediated.

  • Plasmapheresis can be beneficial in COVID-19 patients with autoimmune encephalitis.

Abstract

Severe SARS-CoV-2 (COVID-19) infection has the potential for a high mortality rate. In this paper, we report the results of plasmapheresis treatment in a series of severely ill patients with COVID-19–related autoimmune meningoencephalitis in the Intensive Care Unit (ICU).

Keywords

Autoimmune
Encephalitis
COVID-19
Plasmapheresis

Cited by (0)

1

Dual first authors

View Abstract